Arkolith/Insider Trading/ABUS/Form 4

Manchester Keith S

DirectorArbutus Biopharma Corp (ABUS) · full profile →Form 4 · filed Aug 16, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$33K
Net Open-Market Flow
-$33K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 14, 2024Sell(S)9K$3.69$33K46K
Aug 14, 2024Option exercise(M)55K$0.56$31K55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 14, 2024Option exercise(M)55K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001447028-24-000078) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Arbutus Biopharma Corp

Build

Ask your agent about ABUS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001447028-24-000078"
Ask your agent
Use Arkolith to summarize insider buying and selling at Arbutus Biopharma Corp
over the last 90 days and cite the filings.